Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech

Carolin Barth Is New CEO

The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.

Oxford Science Park, Fletcher House and Winchester House — Miro Bio is headquartered at Oxford Science Park, UK

MiroBio, an emerging biotech focused on developing checkpoint agonist drugs has appointed Carolin Barth, former head of commercial and pipeline strategy, cell and gene therapy at Novartis, as its CEO.

The Oxford, UK-based company came out of stealth mode nearly two years ago with a $34m series A fundraising, and...